Sanochemia: Composition of matter patent in the US on Tolperison granted until 2028

Furthermore, a licensing deal grants marketing rights on Tolperison in North America and other countries to Katama Pharmaceuticals. Additional recent successes include the conclusion of a phase IIb clinical study on Vidon® (PVP-Hyperizin) to detect bladder cancer.

Sorry, this entry is only available in German!

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)